Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DF6Z3C
|
|||
| Drug Name |
SAR444200
|
|||
| Drug Type |
Nanobody
|
|||
| Indication | Aggressive cancer [ICD-11: 2A00-2F9Z; ICD-10: R45.6; ICD-9: 140-229] | Phase 2 | [1] | |
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glypican-3 (GPC3) | Target Info | . | [2] |
| T-cell receptor (TCR) | Target Info | . | [2] | |
| KEGG Pathway | Proteoglycans in cancer | |||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Pathway Interaction Database | Glypican pathway | |||
| Glypican 3 network | ||||
| Reactome | A tetrasaccharide linker sequence is required for GAG synthesis | |||
| HS-GAG degradation | ||||
| Retinoid metabolism and transport | ||||
| WikiPathways | Visual phototransduction | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05450562) A Phase 1/2 Open-label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR444200-based Regimen in Participants With Advanced Solid Tumors. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Sanofi | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.